Inmune Bio director exercises 14,801 warrants
Inmune Bio, Inc. director Juda Scott exercised common stock purchase warrants in a cash transaction, acquiring 14,801 shares of Common Stock at $1.40 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Inmune Bio, Inc. director Juda Scott exercised common stock purchase warrants in a cash transaction, acquiring 14,801 shares of Common Stock at $1.40 per share. This exercise stems from an April 2024 warrant inducement agreement with the company.
Following the transaction, Scott directly owns 86,404 shares of Common Stock. Under the same inducement letter, the maturity date of the remaining 50% of Scott’s April 2024 warrants that were not exercised was extended from June 30, 2026 to December 31, 2027, providing a longer exercise window for those warrants.
Insider Trade Summary
14,801 shares exercised/converted
Exercise
2 txns
Insider
Juda Scott
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Common Stock Purchase Warrant | 14,801 | $0.125 | $2K |
| Exercise | Common Stock | 14,801 | $1.40 | $21K |
Holdings After Transaction:
Common Stock Purchase Warrant — 14,802 contracts (Direct);
Common Stock — 86,404 shares (Direct)
Footnotes (1)
- F1. Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.
Key Figures
Common shares acquired: 14,801 shares
Exercise price: $1.40 per share
Director holdings after transaction: 86,404 shares
+4 more
7 metrics
Common shares acquired
14,801 shares
Shares of Common Stock acquired via warrant exercise on July 2, 2026
Exercise price
$1.40 per share
Cash exercise price for April 2024 warrants
Director holdings after transaction
86,404 shares
Total Common Stock directly owned by Juda Scott after exercise
Warrants exercised
14,801 warrants
April 2024 Warrants exercised representing 50% of Scott’s holdings
Extended warrant expiration
December 31, 2027
New maturity date for remaining 50% of April 2024 Warrants
Original warrant expiration
June 30, 2026
Prior maturity date for unexercised April 2024 Warrants
Warrant transaction price figure
$0.1250
Price figure associated with derivative transaction entry for warrants
Key Terms
Common Stock Purchase Warrant, warrant inducement offer letter agreement, April 2024 Warrants, exercise price, +1 more
5 terms
Common Stock Purchase Warrant financial
"Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person."
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
warrant inducement offer letter agreement financial
"entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter")."
April 2024 Warrants financial
"previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants")."
exercise price financial
"agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
maturity date financial
"in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants"
The maturity date is the specific day when a loan, bond, or investment reaches its full term and the borrower must repay the borrowed amount in full. It is important for investors because it indicates when they will receive their initial money back and can plan their future financial steps accordingly. Think of it as the due date for a loan or the day a gift card or coupon expires.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Inmune Bio (INMB) director Juda Scott report in this Form 4?
Juda Scott reported exercising warrants to acquire 14,801 Inmune Bio common shares. The exercise was a cash transaction at $1.40 per share, increasing Scott’s direct holdings to 86,404 common shares and forming part of a broader April 2024 warrant inducement arrangement.
At what price did Juda Scott exercise Inmune Bio (INMB) warrants on this Form 4?
Scott exercised Inmune Bio common stock purchase warrants at an exercise price of $1.40 per share. The exercise covered 14,801 warrants, resulting in the same number of common shares being issued to Scott in a cash exercise under the inducement agreement.
What are the key terms of the April 2024 warrant inducement for Inmune Bio (INMB)?
Under the inducement, Scott agreed to exercise 14,801 April 2024 warrants for cash at $1.40 per share. In return, Inmune Bio extended the maturity date of the remaining 50% of Scott’s April 2024 warrants from June 30, 2026 to December 31, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
